Humana’s Gain Continues
Humana Inc. (HUM) shares are trading positive on Thursday morning, continuing momentum for the last several days in search of a bounce back to the year-ago levels. On Wednesday, the company reported fourth-quarter profit that beat estimates. Revenue were up 10 percent from the previous year.
Currently, shares are at $426.32 up 6.26 percent from the previous close of $401.22 on a volume of 1,314,040. For the 52-week period, the shares have traded in a range of $351.20-$475.44 on average volume of 1,134,227.
Horace Mann Educators Q4 Profit Down
Horace Mann Educators Corp. (HMN) Tuesday reported fourth-quarter net income of $40.5 million or $0.96 per share, down from $47.8 million or $1.13 per share last year.
Core earnings for the quarter was $40.8 million or $0.97 per share, down from $47.5 million or $1.13 per share last year.
Revenues for the quarter dropped 5.9% to $331.4 million from $352.3 million last year.
Analysts polled by Thomson Reuters expected earnings of $0.75 per share on revenues of $330.07 million. Analysts’ estimates typically exclude one-time items.
‘COVID hit 300 of 403 regional air routes’
It says only 22 of 94 routes awarded in inaugural round are operational
The Ministry of Civil Aviation said as many as 300 of the 403 routes operationalised under the regional connectivity (RC) scheme of the government have been hit following the pandemic.
In four different rounds of biddings carried out in the past five years, as many as 948 routes have been awarded.
“Among 403 routes that have commenced operations so far, nearly 300 routes have been affected due to poor demand on account of COVID-19 pandemic situation,” the Ministry of Civil Aviation had told the Parliamentary Standing Committee on Transport, Tourism and Culture which tabled its report on Wednesday.
It had also said that of the 94 RCS routes that were allocated in the inaugural round of bidding in 2017, only 22 routes were in operation.
The Ministry has cited several reasons for the failure of these routes, including challenging aviation business that involves high operational costs and low earnings, non-availability of planes, maintenance issues as well as non-availibility of funds for carrying out development of works at airports.
Opinion | Georgetown Law, Don’t Punish Your New Hire for His Bad Tweets
By Michelle Goldberg
Opinion | W.E.B. Du Bois Would Have Seen Right Through the C.R.T. Backlash
By Jamelle Bouie
Opinion | The Dissenters Trying to Save Evangelicalism From Itself
By David Brooks
CBOE Global Markets, Inc. Q4 Profit Increases, beats estimates
CBOE Global Markets, Inc. (CBOE) reported a profit for its fourth quarter that increased from last year and beat the Street estimates.
The company’s earnings came in at $165.3 million, or $1.54 per share. This compares with $87.1 million, or $0.81 per share, in last year’s fourth quarter.
Excluding items, CBOE Global Markets, Inc. reported adjusted earnings of $181.7 million or $1.70 per share for the period.
Analysts on average had expected the company to earn $1.53 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.
The company’s revenue for the quarter rose 2.6% to $866.4 million from $844.2 million last year.
CBOE Global Markets, Inc. earnings at a glance (GAAP) :
-Earnings (Q4): $165.3 Mln. vs. $87.1 Mln. last year.
-EPS (Q4): $1.54 vs. $0.81 last year.
-Analyst Estimate: $1.53
-Revenue (Q4): $866.4 Mln vs. $844.2 Mln last year.
Regeneron Pharmaceuticals Q4 Profit Increases, beats estimates
Regeneron Pharmaceuticals (REGN) announced earnings for its fourth quarter that increased from the same period last year and beat the Street estimates.
The company’s earnings came in at $2.23 billion, or $19.69 per share. This compares with $1.15 billion, or $10.24 per share, in last year’s fourth quarter.
Excluding items, Regeneron Pharmaceuticals reported adjusted earnings of $2.71 billion or $23.72 per share for the period.
Analysts on average had expected the company to earn $18.02 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.
The company’s revenue for the quarter rose 104.5% to $4.95 billion from $2.42 billion last year.
Regeneron Pharmaceuticals earnings at a glance (GAAP) :
-Earnings (Q4): $2.23 Bln. vs. $1.15 Bln. last year.
-EPS (Q4): $19.69 vs. $10.24 last year.
-Analyst Estimate: $18.02
-Revenue (Q4): $4.95 Bln vs. $2.42 Bln last year.
Flex Shares Up 6%; Gets $500 Mln Investment In Nextracker From TPG
Shares of Flex Ltd. (FLEX) are gaining nearly 6% on Thursday morning after the company announced $500 million investment in Nextracker from TPG Rise Climate.
FLEX is currently trading at $17.75, up $1.00 or 5.97%, on the Nasdaq.
Flex Thursday announced a deal to sell $500 million of convertible preferred equity in Nextracker to TPG Rise Climate
“Through this strategic partnership and investment from TPG Rise Climate, Nextracker will continue to expand its market leading position in solar tracking and software solutions. TPG’s experience and extensive network in renewable energy provide Nextracker a strong partner to support long-term growth,” the company said in a statement.